Loading file
  • Fullscreen
  • Wireframe
  • Zoom In
  • Zoom Out
  • Rotation
  • Screenshot
  • Help

Controls

×
  • Rotate with the left mouse button.
  • Zoom with the scroll button.
  • Adjust camera position with the right mouse button.
  • Double-click to enter the fullscreen mode.
  • On mobile devices swipe to rotate.
  • On mobile devices pinch two fingers together or apart to adjust zoom.
  • On mobile devices 3 finger horizontal swipe performs panning.

4-AcO-DMT

C$27.50C$700.00

Clear

Tryptamines. 4-AcO-DMT.

4-AcO-DMT, aka O-acetylpsilocin, is a novel tryptamine discovered by Albert Hoffman in the 1950s. It is an O-acetate ester of psilocin. It is closely related to psilocin and psilocybin. It is essentially the same molecule as psilocybin, but the phosphate group is replaced with an acetate group. Both hydrolyze readily into psilocin, the centrally active compound which elicits psychedelic effects by binding to the serotonin receptors.

While there are studies done on the use of serotonin 5-HT2A agonists in treating substance/drug use disorders, the neurological basis of these effects have yet to be elucidated. There is an interesting study done on the effects of 4-Aco-DMT on drug-dependent rats and mice, published in the European Journal of Neuroscience (EJN) (Vargas-Perez et al.).

Chronic use of drugs of abuse produce changes and cellular adaptations in neurons located in the VTA (Ventral Tegmental Area) of the brain, which is part of the dopamine mediated reward pathway. These adaptations are mediated by BDNF (brain-derived neurotrophic factor) and are associated with the aversive withdrawal motivation that leads to a drug-dependent state. There is growing evidence that suggests that 5-HT2A receptor signaling can regulate the expression of BDNF in the brain. Both 5-HT and TrkB singaling are involved in modulating long term neuronal survival and plasticity but it is still unknown if these effects occur via a direct 5HT2A/TrkB interaction or downstream interactions between 5HT2A signalling/BDNF signalling.

In a study done with 4-Aco-DMT, it was observed that a single administration to the VTA of rats and mice blocks the aversive conditioned response to drug withdrawal as well as the mechanism that switches the drug-naive state to a drug-dependent system.

These studies indicated that 5-HT2A agonists can be used as therapeutic agents to reverse drug dependency and inhibit the aversive withdrawal response.

Our batch of 4-AcO-DMT has been used in scientific research as a standard for purity analysis, and has been confirmed as near 100% purity in a published paper from the University of Massachusetts (Chadeayne et al.).

It is NOT intended for human consumption, and is strictly for laboratory reagent or forensic analysis purposes ONLY. Available as the fumarate salt.

All prices are listed in Canadian dollars.

Citations:

Vargas-Perez, Hector, et al. “A Single Administration of the Hallucinogen, 4-Acetoxy-Dimethyltryptamine, Prevents the Shift to a Drug-Dependent State and the Expression of Withdrawal Aversions in Rodents.” European Journal of Neuroscience, vol. 45, no. 11, 2017, pp. 1410–1417., doi:10.1111/ejn.13572.

Chadeayne, Andrew R., et al. “Bis(4-Acetoxy-N,N-Dimethyltryptammonium) Fumarate: a New Crystalline Form of Psilacetin, an Alternative to Psilocybin as a Psilocin Prodrug.” Acta Crystallographica Section E Crystallographic Communications, vol. 75, no. 6, 2019, pp. 900–902., doi:10.1107/s2056989019007370.

Purity Analysis

92292-84-7 HNMR(1)
LC-MS

MSDS

Please refer to the attached MSDS (Material Safety Data Sheet) for instructions on safely handling 4-AcO-DMT.

4acodmt